Clinical Trial: A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
Study Status: Completed
Recruit Status: RECRUITING
Condition: Cryopyrin Associated Periodic Syndrome
Study Type: INTERVENTIONAL
Official Title: A Phase 2A, Single-Arm Study to Evaluate the Safety and Clinical Activity of VTX2735 in Participants With Cryopyrin-Associated Periodic Syndrome (CAPS)
Brief Summary:
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS).Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B.The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period.The maximum length of treatment is 4 weeks.
Read more